本文關(guān)鍵詞： 精神分裂癥 首發(fā) 妊娠 利培酮 喹硫平 齊拉西酮 妊娠結(jié)局　出處：《基因組學(xué)與應(yīng)用生物學(xué)》2017年04期 　論文類型：期刊論文

【摘要】：探討利培酮、喹硫平和齊拉西酮對(duì)首發(fā)女性精神分裂癥妊娠患者糖脂代謝及妊娠結(jié)局的影響。選取2012年7月~2014年7月我院收治的首發(fā)精神分裂癥孕婦97例作為研究對(duì)象,根據(jù)治療方案分為利培酮組(27例)、喹硫平組(36例)、齊拉西酮組(34例),均治療8周。記錄臨床療效、不良用藥反應(yīng)和不良妊娠結(jié)局,治療前后采用陽性和陰性綜合征量表(PANSS)、簡明精神病量表(BPRS)檢測精神分裂癥嚴(yán)重程度,檢測治療前后體質(zhì)量(BMI)及糖脂水平。結(jié)果發(fā)現(xiàn),3組患者臨床療效、妊娠結(jié)局、不良用藥反應(yīng)比較無明顯差異(p0.05),3組治療后PANSS、BPRS評(píng)分均下降,差異具有統(tǒng)計(jì)學(xué)意義(p0.05),但3組治療后組間比較無差異(p0.05);3組患者治療前后空腹血糖(FPG)、餐后2 h血糖(2h PBG)、膽固醇(TC)無明顯變化(p0.05);3組治療后BMI、血清胰島素(FINS)、甘油三酯(TG)均有所改變,同組治療前后差異顯著(p0.05);其中喹硫平組BMI上升幅度較齊拉西酮組明顯(p0.05),利培酮組FINS下降,喹硫平組、齊拉西酮組均上升,利培酮組FINS低于喹硫平組、齊拉西酮組,差異有統(tǒng)計(jì)學(xué)意義(p0.05)。因此,利培酮、喹硫平、齊拉西酮對(duì)首發(fā)女性精神分裂癥孕婦的精神分裂癥狀改善療效一致,但易致糖脂代謝紊亂,存在一定風(fēng)險(xiǎn)。
[Abstract]:To investigate the effects of risperidone, quinolipine and ziprasidone on glucose and lipid metabolism and pregnancy outcome in first-episode female schizophrenic pregnancy, 97 first-episode schizophrenic pregnant women admitted to our hospital from July 2012 to July 2014 were selected as subjects. The patients were divided into risperidone group (n = 27), quetiapine group (n = 36) and ziprasidone group (n = 34) for 8 weeks. Positive and negative syndrome scale (PANSS), brief Psychiatric scale (BPRS) were used before and after treatment to detect the severity of schizophrenia, body mass and serum glucose and lipid levels before and after treatment. There was no significant difference in adverse drug reactions among the three groups. After treatment, the scores of PANSS and BPRS were all decreased. The difference was statistically significant (P 0.05), but there was no significant difference between the three groups after treatment. There was no significant change in fasting blood glucose (FBG) before and after treatment, 2 h postprandial blood glucose (2 h PBGG), and no significant change in cholesterol (TCc) after treatment. There were no significant changes in BMIs, serum insulin and triglyceride (TG) levels in the three groups after treatment. There was a significant difference between the same group before and after treatment (p 0.05), in which the increase of BMI was significantly higher in quetiapine group than in ziprasidone group, the FINS in risperidone group was decreased, and the FINS in risperidone group was lower than that in ziprasidone group, and the FINS in risperidone group was lower than that in ziprasidone group. Therefore, risperidone, quetiapine and ziprasidone have the same effect on the improvement of schizophrenic symptoms in first-episode female schizophrenic women, but they are prone to lead to disorder of glucose and lipid metabolism, and there are certain risks.
【作者單位】： 武漢市精神衛(wèi)生中心;
【基金】：武漢市衛(wèi)生局課題資助(WX08D21)資助
【分類號(hào)】：R714.2;R749.3
，

本文編號(hào)：1529338